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Aberrant activation of Wnt/β-catenin signaling plays a key role in the onset and development of hepatocellular
carcinomas (HCC), with about half of them acquiring mutations in either CTNNB1 or AXIN1. However, it remains
unclear whether these mutations impose sufficient β-catenin signaling or require upstream Wnt ligand activation
for sustaining optimal growth, as previously suggested for colorectal cancers. Using a panel of nine HCC cell lines,
we show that siRNA-mediated knockdown of β-catenin impairs growth of all these lines. Blocking Wnt secretion,
by either treatment with the IWP12 porcupine inhibitor or knockdown of WLS, reduces growth of most of the lines.
Unexpectedly, interfering with Wnt secretion does not clearly affect the level of β-catenin signaling in the majority
of lines, suggesting that other mechanisms underlie the growth-suppressive effect. However, IWP12 treatment
did not induce autophagy or endoplasmic reticulum (ER) stress, which may have resulted from the accumulation
of Wnt ligands within the ER. Similar results were observed for colorectal cancer cell lines used for comparison in
various assays. These results suggest that most colorectal and liver cancers with mutations in components of the
β-catenin degradation complex do not strongly rely on extracellular Wnt ligand exposure to support optimal
growth. In addition, our results also suggest that blocking Wnt secretion may aid in tumor suppression through
alternative routes currently unappreciated.
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Hepatocellular carcinoma (HCC) is considered as the fifth most
common cancer and the third main reason for cancer-related death
with 748,000 cases and 695,000 deaths each year [1,2]. The etiology
of HCC includes hepatitis B virus or hepatitis C virus infection,
alcohol liver disease, nonalcoholic steatohepatitis, and aflatoxin-B1
exposure [3]. More than 80% of all HCCs occur in Eastern and
Southeastern Asia where the main cause is hepatitis B virus combined
with exposure to aflatoxin-B1 [4]. In Europe, Japan, and the United
States, hepatitis C virus represents the dominant risk factor, together
with alcohol abuse and nonalcoholic fatty liver diseases [5,6].
Wnt/β-catenin signaling plays an important role in a wide range of
biological processes, involving embryonic patterning, cell prolifera-
tion, differentiation, angiogenesis, carcinogenesis, metastasis, and
drug resistance [7–9]. Underscoring the relevance of this pathway,
many tumor types including HCC exhibit enhanced Wnt/β-catenin
signaling that strongly contributes to tumor growth [10]. Activation
of Wnt/β-catenin signaling starts with the secretion of Wnt ligands.
Wnts produced within the endoplasmic reticulum (ER) arepalmitoylated by the Wnt acyl-transferase porcupine (PORCN),
which is essential for their secretion and signaling activity. Following
this lipid modification, Wntless (WLS) is needed to shuttle the Wnt
proteins from the Golgi to the plasma membrane where they can
signal in an autocrine or paracrine manner [11]. In the absence of
upstream Wnt signaling, β-catenin is phosphorylated at N-terminal
Ser/Thr residues by a multiprotein complex consisting of the
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proteins AXIN1, AXIN2 and AMER1, and the kinases GSK3 and
CK1α. Phosphorylated β-catenin is then ubiquitinated, leading to its
proteasomal degradation [12–14]. The overall effect is low β-catenin
levels in the cytoplasm and nucleus of unstimulated cells.
Upon binding of Wnt ligands to Frizzled and LRP5/6 co-receptors,
Disheveled (DVL) becomes phosphorylated, subsequently resulting in
the inhibition of the β-catenin destruction complex [15]. As a result,
β-catenin is stabilized and is able to translocate to the nucleus and
associate with members of the TCF/LEF family of transcription factors,
thus regulating the expression of specific downstream Wnt/β-catenin
target genes and thereby affecting cellular decisions [4]. In addition to
this classical (canonical)Wnt signaling pathway,Wnts can also signal in
an alternative (noncanonical) fashion independent of β-catenin through
associating with Frizzled and ROR1/2 receptors instead of LRP5/6.
Activation of noncanonical Wnt signaling mainly affects cellular
processes involved in migration and cellular polarity [8].
Hepatocarcinogenesis is amultistep process, progressing from a normal
hepatocyte to a transformed phenotype as a result of the accumulation of
aberrant genetic and epigenetic modifications and activation of various
signaling pathways [16–18]. Increasing evidence indicates that activation
of Wnt/β-catenin signaling is critical in hepatic oncogenesis [19,20].
About 40% to 70% of HCCs are characterized by nuclear accumulation
of β-catenin, the hallmark of active signaling. Various molecular and
genetic alterations contribute to aberrant activation of Wnt/β-catenin
signaling. Mutations within components of the canonical Wnt/β-catenin
signaling enhance stabilization of β-catenin and transcriptional activity in
the nucleus. Approximately one third of all HCCs carry oncogenic
β-catenin mutations within exon 3 at the N-terminal phosphorylation
residues, making the protein more resistant to proteolytic degradation
[21]. In another subset of tumors, loss-of-function mutations of negative
regulators are observed in the APC and AXIN1 genes, respectively in 1%
to 3% and 8% to 15% of tumors [19], both causing compromised ability
to degrade β-catenin [8]. In addition to mutations, various other
mechanisms have been suggested to promote β-catenin signaling,
including overexpression of Wnt ligands and/or their corresponding
receptors, and reduced expression of extracellular inhibitors [22]. Given
the importance of β-catenin signaling for hepatic oncogenesis, various
treatments targeting this route have been evaluated [23].
Cancers harboring mutations within intracellular components of the
β-catenin signaling pathway, i.e., mutation of APC, AXIN or β-catenin
itself, were often considered to become largely independent of upstream
regulation by extracellular Wnt ligands. This belief has however been
challenged during the last years. For example, Wnt antagonists SFRPs
and DKKs are reported to attenuate Wnt signaling in colorectal cancer
(CRC) [24,25]. Recently, it was demonstrated that interfering with
Wnt secretion or reducing the expression of specific Wnt ligands
impaired the growth of APC and β-catenin mutant CRC cell lines [26].
These results also indicated that interfering with Wnt secretion, for
example, using the newly developed PORCN inhibitors [27,28], could
be useful as an additive treatment option for tumors characterized by
enhanced β-catenin signaling. Here, we have investigated whether this
also holds truth for β-catenin or AXIN1 mutant liver cancer cells.
Materials and Methods
Cell Lines
Human HCC cell lines Hep3B, Huh6, Huh7, PLC/PRF/5,
SNU182, SNU398, and SNU449, and CRC cell lines CACO2,DLD1, HT29, SW480, HCT116, LS174T, SW48, and RKO were
cultured in Dulbecco's modified Eagle’s medium (Invitrogen-Gibco,
Breda, the Netherlands) complemented with 10% (v/v) fetal calf
serum (Hyclone, Lonan, UT), 100 IU/ml penicillin, 100 μg/ml
streptomycin, and 2 mM L-glutamine (Invitrogen-Gibco). The
hepatoblastoma cell line HepG2 was cultured on fibronectin/
collagen/albumin-coated plates (AthenaES) in Williams E medium
(Invitrogen-Gibco, Breda, the Netherlands) complemented with
10% (v/v) fetal calf serum, 100 IU/ml penicillin, 100 μg/ml
streptomycin, and 2 mM L-glutamine. HepaRG was cultured in
William's E medium supplemented with 10% (v/v) fetal calf serum,
100 IU/ml penicillin, 100 μg/ml streptomycin, 5 μg/ml insulin
(Sigma-Aldrich, St. Louis, MO), and 50 μM hydrocortisone
hemisuccinate (Sigma-Aldrich, St. Louis, MO). Identity of all cell
lines was confirmed by STR genotyping. CTNNB1 mutation status
was confirmed in all the nine HCC cell lines by Sanger sequencing
and was consistent with those reported at the Catalogue of Somatic
Mutations in Cancer (http://cancer.sanger.ac.uk) [29].
For the preparation of conditioned medium, L-control and
L-Wnt3A cells were cultured in complete Dulbecco's modified
Eagle’s medium, followed by collection and filtration of medium
according to standard procedures. HCC and CRC cell lines were
stimulated with 25% L-control or L-Wnt3A medium.
Reagents
IWP12 (Sigma-Aldrich, St. Louis, MO) was dissolved in dimethyl
sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) with a final stock
concentration of 10 mM. Antibodies specific for β-catenin (cat. #9561,
Cell Signaling Technology), disheveled adaptor protein (DVL2) (cat.
#3216, Cell Signaling Technology), WLS (cat. #MABS87, clone YJ5
Millipore), LC3I/II (cat. #4108, Cell Signaling Technology),
GPR177(Wls/Evi) (cat. #MABS87, Millipore) and β-actin (sc-47,778,
Santa Cruz), Tubulin (sc-8035, Santa Cruz) anti-rabbit or anti-mouse
IRDye-conjugated secondary antibodies (Stressgen, Glandford Ave,
Victoria, BC, Canada) were used for western blot analysis.
Gene Knockdown by Small Interfering RNA (siRNA)
Smartpool ON-TARGETplus siRNAs targeting CTNNB1 and
WLS were obtained from Dharmacon. The ON-TARGETplus
nontargeting siRNA #2 was used as negative control. Cells were
reverse-transfected in a 96-well plate using a total of 0.2 μl
DharmaFECT formulation 4 (Thermo Fischer Scientific) and 25
nM of each siRNA per well. Following 72 hours of incubation, the
effect on knockdown was determined by Western blotting.
Quantitative Real-Time Polymerase Chain Reaction (PCR)
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke,
Leiden, the Netherlands) and quantified using a Nanodrop ND-1000
(Wilmington, DE). cDNA was prepared from total RNA using a
cDNA Synthesis Kit (TAKARA BIO INC.) and subjected to
quantitative real-time PCR analyses. Analyses were performed using
the StepOne Real-Time PCR System and the StepOnev2.0 software
(Applied Biosystem, Darmstadt, Germany). Primer sequences are
provided in Supplementary Table 1. All expression levels are depicted
relative to the expression of GAPDH.
Western Blot Assay
Cells were lysed in Laemmli sample buffer with 0.1 M DTT and
heated for 5 to 10 minutes at 95°C, followed by loading and
able 1. Gene Mutations of Wnt/β-Catenin Signaling Components in HCC and CRC Cell Lines
ell Line Gene AA Alteration Zygosity
CC
HepG2 CTNNB1 p. W25_I140 del Heterozygous
Huh6 CTNNB1 p. G34 V Heterozygous
SNU398 CTNNB1 p. S37C Heterozygous
Hep3B AXIN1 p. R146* Homozygous
PLC/PRF/5 AXIN1 p.(R373_M418 del) Homozygous
SNU449 AXIN1 p. R712* Homozygous
Huh7
HepaRG
SNU182
RC
SW480 APC p. Q1338* Homozygous
HT29 APC p. T1556 fs*3 Heterozygous
p. E853* Heterozygous
Caco2 APC p. Q1367* Homozygous
DLD1 APC p. R2166* Heterozygous
p. I1417fs*2 Heterozygous
AXIN1 p. L396 M Heterozygous
RNF43 p. G659 fs*41 Heterozygous
SW48 CTNNB1 p. S33Y Heterozygous
RNF43 p. G659 fs*41 Heterozygous
p. V299 fs*143 Heterozygous
HCT116 CTNNB1 p. S45del Heterozygous
RNF43 p. R117fs*41 Homozygous
LS174T CTNNB1 p. S45F Homozygous
RKO RNF43 p. G659 fs*41 Homozygous
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gels. After 90 minutes of running at 120 V, proteins were
electrophoretically transferred onto a polyvinylidene difluoride
membrane (Invitrogen) for 1.5 hours with an electric current of
250 mA. Subsequently, the membrane was blocked with 2.5 ml
Odyssey Blocking Buffer and 2.5 ml PBS containing 0.05% Tween
20, followed by incubation with primary antibody (all 1:1000)
overnight at 4°C. The membrane was washed 3 times with PBS
containing 0.05% Tween 20 followed by incubation for 1.5 hours
with anti-rabbit or anti-mouse IRDye-conjugated secondary anti-
bodies (LI-COR Biosciences, Lincoln, NE) (1:5000) at room
temperature. Blots were assayed for β-actin or Tubulin content as
standardization of sample loading, scanned, and quantified by
Odyssey infrared imaging (Li-COR Biosciences, Lincoln,
NE). Results were visualized and quantified with Odyssey 3.0
software.
β-Catenin Reporter Assays
The β-catenin reporter assays were basically performed as
previously described [30,31]. In short, 20 hours before transfection,
we plated 105 cells per well on 12-well plates. Each well was
transfected with 500 ng Wnt Responsive Element (WRE) or Mutant
Responsive Element (MRE) vectors and 20 ng TK-Renilla using
polyethylenimine (PEI) (Sigma-Aldrich, St. Louis, MO) or Fugene
HD (Promega). We measured luciferase activities in a LumiStar
Optima luminescence counter (BMG LabTech, Offenburg, Germa-
ny) and normalized the data for the transfection efficiency by using
the Dual Luciferase Reporter Assay system (Promega) according to
the manufacturer's instruction. Transfections were performed in
triplicate, and the mean and standard error were calculated for each
condition. The β-catenin reporter activities are shown as WRE/MRE
ratios.
MTT Assay
A total of 10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) (Sigma) was added to cells seeded in 96-well plates and
incubated at 37°C with 5% CO2 for 3 hours. The medium was removed,
and 100 μl DMSO was added to each well. The absorbance of each well
was read on a microplate absorbance reader (BIO-RAD) at wavelength of
490 nm. For siRNA-mediated knockdown of genes, four independent
wells were assayed for each cell line at least two times, whereas for
IWP12 treatment, six independent wells were used. The mean and
standard error were calculated for each condition.
Cell Cycle Analysis
At around 60% to 80% confluency, cells were trypsinized and
washed with PBS and then fixed in cold 70% ethanol overnight at
4°C. The cells were washed twice with PBS and incubated with 20
μg/ml RNase at 37°C for 30 minutes followed by incubation with 50
μg/ml propidium iodide at 4°C for 30 minutes. Then samples were
tested immediately by FACS. Cell cycle was analyzed by FlowJo_V10
software. For each treatment, two independent wells were tested for
Huh6, SNU449 and Huh7 two times. The mean and standard error
were calculated for each condition.
Statistical Analysis
All results were presented as mean ± SD. Comparisons between
groups were performed with one-sample t test. Differences were
considered significant at a P value less than .05.Results
β-Catenin Signaling Activity of HCC Cell Lines
To investigate the importance of β-catenin signaling and Wnt
secretion for sustaining cell growth, we employed nine HCC cell
lines, listed in Table 1 in which gene mutations related to Wnt/
β-catenin signaling are depicted. We also used eight CRC cell lines for
comparison in various assays, known to largely depend on β-catenin
signaling for their growth. First, we determined the baseline β-catenin
signaling activity for all these cell lines using a β-catenin reporter assay
and qRT-PCR of AXIN2, a well-established β-catenin target gene. As
indicated in Figure 1, in line with previous publications, all β-catenin
mutant HCC lines (SNU398, HepG2 and Huh6) showed a robust
induction of both reporter activity as well as high AXIN2 expression.
The AXIN1 mutant lines (PLC/PRF/5, Hep3B, and SNU449) also
displayed enhanced reporter activity, albeit generally more modest,
whereas the expression of AXIN2 was low. Interestingly, among the
HCC lines without an obvious mutation, SNU182 presented with
high β-catenin signaling activity, both on reporter level and on
AXIN2 expression. Huh7 and HepaRG showed low reporter activity
together with low AXIN2 expression. All CRC lines, except RKO
being wild type for APC and CTNNB1, showed the expected increase
in reporter activity (Figure S1).
Requirement for β-Catenin Signaling to Sustain Efficient Cell
Growth
Next, we determined the dependence on β-catenin signaling for
supporting efficient growth by transiently transfecting smartpool
siRNAs targeting CTNNB1 or a control siRNA, followed by an
MTT assay to test cell numbers after 3 days of culture. For most cell
lines, we accomplished more than 80% knockdown of β-catenin at
protein level as determined by quantitative Western blot analysis, with
the exception of HepaRG in which a 65% reduction was observed
(Figure 2A and Supplemental Figure S2). As indicated in Figure 2B,
β-catenin signaling activity was clearly suppressed by siRNA-mediatedT
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Figure 1. Baseline β-catenin signaling activity in HCC cell lines. (A) β-Catenin luciferase reporter assay showing β-catenin signaling activity
in HCC cell lines (mean ± SD, n = 3). The β-catenin reporter activities are depicted as WRE/MRE ratios. (B) qRT-PCR assay showing
expression of the β-catenin target gene AXIN2 in HCC cell lines (mean ± SD, n = 3). Expression levels are depicted relative to the
housekeeping gene GAPDH.
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SNU449 and Huh7. All HCC cell lines were inhibited significantly in
their growth (Figure 2C), suggesting that β-catenin signaling is
important for the growth of these tumor cells, even in the ones that
show only low tomodest levels of signaling, such asHuh7 andHepaRG.
Cell cycle analysis in three lines showed that β-catenin knockdown
provoked a dramatic G0/G1 phase arrest in Huh6 (Figure 2D). Also in
Huh7, a notable increase of cells in G0/G1 is observed with a significant
reduction of cells in the G2/M phase, whereas for SNU449, a trend is
observed toward more cells in G0/G1 and less cells in S-phase. As
expected, all five tested CRC cell lines showed a significantly reduced
growth upon β-catenin knockdown (Figure 2E).
Expression Levels of WNT Ligands in HCC Cell Lines
Taken together, the results above indicate that targeting the
β-catenin signaling pathway represents an attractive route to suppress
the growth of HCCs. This pathway has however been refractory to
target in an efficient manner. More recently, inhibitors of Wnt
secretion have been proposed as treatment options for malignancies
dependent on Wnt-ligand secretion for their growth [26–28].
However, a prerequisite is that the tumor cells express sufficient
levels of Wnt ligands capable of inducing β-catenin signaling. Hence,
we investigated the expression profile of all 19 Wnt ligand genes in
our HCC cell line panel by qRT-PCR. From the group of Wnt
ligands more commonly associated with inducing β-catenin signaling
(WNT1, 2, 3, 3A, 8A, 8B, 10A, and 10B), only WNT3 was clearly
expressed in all HCC cell lines, followed by high WNT10A
expression restricted to the SNU182 and HepaRG cell lines and
high WNT2 expression in SNU449 (Figure 3A). The remaining
ligands of this group are barely detectable or expressed at least at
10-fold lower levels in all cell lines (Figure S3). When piling up the
expression of all Wnt ligands from this group (Figure 3B), the
SNU182 cell line clearly stands out as one with overall highest
expression level, which may explain its high β-catenin signaling
activity reported above. The β-catenin and AXIN1 mutant cell lines
are among the low-to-intermediate ones.
Among the group of Wnt ligands more commonly associated with
activating alternative pathways (WNT4, 5A, 5B, 6, 7A, 7B, and 11)depicted in Figure S4A, WNT5A was most prominently expressed,
being very high in HepaRG and SNU182 and readily detectable in
SNU398 and SNU449. The latter cell line also shows high expression
of WNT5B and WNT7B. Other Wnt ligands of this group are
detectable only at low levels or absent within most cell lines. Overall,
SNU182 is again the most prominent expressing cell line, whereas the
β-catenin and AXIN1 mutant cell lines are among the
low-to-intermediate expressers (Figure 3B). Of the remaining Wnt
ligands (WNT2B, 9A, 9B, and 16), WNT2B was highly expressed in
PLC/PRF/5, SNU182, SNU398, and SNU449, whereas WNT9B
was clearly expressed in Hep3B (Supplemental Figure S4B).
Combining the expression of all Wnt ligands shows that SNU182
has again the highest overall levels, followed by HepaRG and
SNU449 (Figure 3B, right panel). As all Wnt ligands trigger the
phosphorylation of DVL2 upon binding of either the FZD_LRP5/6
or FZD_ROR1/2 receptor complexes [32,33], we determined
baseline pDVL2 levels in all cell lines. As shown in Figure 3C, the
highest levels of phosphorylated DVL2 are observed in the three cell
lines with the highest Wnt levels, whereas for the remaining six lines,
no clear correlation can be observed.
In summary, although all HCC cell lines show a large variation in
Wnt ligand expression, they all express Wnt ligands that can
contribute to β-catenin signaling.
Wnt Secretion Blockage Reduces Growth of HCC Cells
Given that most HCC cell lines show increased β-catenin signaling
activity and expression of canonical Wnt ligands, we wished to
investigate the consequences of suppressing the secretion of Wnt
ligands. To this aim, we used two methods, i.e., treatment with
IWP12, an effective inhibitor of PORCN required for palmitoylation
of Wnt proteins [34], and knockdown of WLS, which shuttles the
palmitoylated Wnts from the Golgi to the plasma membrane. Both
treatments are expected to reduce overall levels of secreted Wnt
ligands. Following 3 days of IWP12 treatment, reduced cell numbers
were observed for all β-catenin mutant cell lines (Figure 4A), ranging
from 10% reduction (Huh6) to 35% (SNU398). Among the
nonmutant lines, growth of HepaRG was strongly suppressed by
IWP12, whereas Huh7 and SNU182 showed more modest
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Figure 2. Requirement of β-catenin signaling for sustaining HCC cell growth. (A) HCC cell lines were transiently transfected with CTNNB1
siRNAs for 72 hours. Cell lysates were collected for Western blotting with indicated antibodies. Tubulin and β-actin served as loading
control (LC). (B) Silencing of β-catenin caused the reduction of β-catenin signaling activity (mean ± SD, n= 2, two times). (C) Silencing of
β-catenin inhibited the growth of HCC cell lines as determined by MTT assay (mean ± SD, n = 4, two times). (D) Silencing of β-catenin
alters cell cycle progression in Huh6 (all phases significantly changed) and Huh7 cells (G2/M phase significantly reduced). SNU449 is less
clearly altered, although the proportion of cells in S-phase is reduced (mean ± SD, n = 2, two times). (E) β-catenin knockdown reduced
cell growth in colorectal cancer cell lines. Values depicted are relative to the ones obtained with the nontargeting siRNA that are arbitrarily
set to 1. *P b .05; **P b .01.
Neoplasia Vol. 18, No. 12, 2016 Blocking Wnt Secretion Reduces Growth of HCC Wang et al. 715reductions of their growth. The AXIN1 mutant lines were not clearly
affected by IWP12 with the exception of PLC/PRF/5. Effects on
growth following knockdown of WLS were largely in line with
IWP12 treatment, with the exception of the AXIN1 mutant linesHep3B and SNU449 that were significantly suppressed by WLS
knockdown and a less impressive growth reduction of HepaRG when
compared with IWP12 (Figure 4B). Examples of efficient WLS
knockdown are shown in Supplemental Figure S5.
AB
C
CTNNB1 mutant
AXIN1 mutant
pDVL2
   DVL2
38    22  19  19  10 40     42  24  66
WNT3
He
pG
2
Hu
h6
SN
U3
98
He
p3
B
PL
C/P
RF
/5
SN
U4
49
Hu
h7
He
pa
RG
SN
U1
82
0.00
0.01
0.02
0.03
0.04
0.05
R
N
A 
le
ve
l r
el
at
iv
et
o 
G
AP
DH
WNT10A
He
pG
2
Hu
h6
SN
U3
98
He
p3
B
PL
C/P
RF
/5
SN
U4
49
Hu
h7
 
He
pa
RG
SN
U1
82
0.00
0.01
0.02
0.03
0.04
0.05
R
N
A 
le
ve
l r
el
at
iv
e 
to
 G
AP
DH
WNT2
He
pG
2
Hu
h6
SN
U3
98
He
p3
B
PL
C/P
RF
/5
SN
U4
49
Hu
h7
He
pa
RG
SN
U1
82
0.00
0.01
0.02
0.03
0.04
R
N
A 
le
ve
l r
el
at
iv
e 
to
 G
AP
DH
Canonical WNTs
He
pG
2
Hu
h6
SN
U3
98
He
p3
B
PL
C/P
RF
/5
SN
U4
49
Hu
h7
He
pa
RG
SN
U1
82
0.00
0.02
0.04
0.06
0.08
0.10
R
N
A 
le
ve
l r
el
at
iv
e 
to
 G
AP
DH
Noncanonical WNTs
He
pG
2
Hu
h6
SN
U3
98
He
p3
B
PL
C/P
RF
/5
SN
U4
49
Hu
h7
He
pa
RG
SN
U1
82
0
1
2
3
4
R
N
A 
le
ve
l r
el
at
iv
e 
to
 G
AP
DH
WNTs
He
pG
2
Hu
h6
SN
U3
98
He
p3
B
PL
C/P
RF
/5
SN
U4
49
Hu
h7
He
pa
RG
SN
U1
82
0.0
0.4
0.8
2
3
4
R
N
A 
le
ve
l r
el
at
iv
e 
to
 G
AP
DH
Figure 3. Expression levels of Wnt family members in HCC cell lines determined by qRT-PCR. (A) Expression levels of the top three
expressed “canonical”Wnt ligands (mean± SD, n=3). (B) Piled-up expression levels of canonical, noncanonical, and overall Wnt ligands,
respectively. All expression levels are depicted relative to the housekeeping gene GAPDH. (C) Baseline levels of phosphorylated DVL2
(pDVL2) in all HCC cell lines. Values below the image represent percentage of total DVL2 that is in the phosphorylated form (upper band).
716 Blocking Wnt Secretion Reduces Growth of HCC Wang et al. Neoplasia Vol. 18, No. 12, 2016For comparison, the same assays were also performed on five CRC
cell lines (Figure 4, C and D). Both treatments showed the strongest
growth suppression when applied to the β-catenin and RNF43
mutant HCT116 cell line. Intermediate effects were observed in
DLD1, HT29, and SW480, whereas CACO2 was barely affected. In
conclusion, most HCC and CRC cell lines are suppressed in their
growth by both IWP12 treatment as well as WLS knockdown.
Altered Exposure to Extracellular Wnt Ligands Does Not Affect
β-Catenin Signaling Activity in Most HCC Cell Lines
Previously, it was reported that Wnt secretion is required to
maintain sufficiently high levels of canonical Wnt/β-catenin signaling
activity in both APC and β-catenin mutant CRC cell lines [26]. Here,
we asked whether the β-catenin and AXIN1 mutant HCC cell lines
were also dependent on Wnt secretion to sustain this pathway
activity. Exposure to extracellular Wnt ligands was again reduced by
treating all cell lines with IWP12, after which we measured β-catenin
signaling activity using the reporter assay and AXIN2 qRT-PCR.After 48 hours, β-catenin reporter activity was clearly suppressed only
in SNU182 (Figure 5A), whereas the remaining eight HCC lines were
not or only modestly inhibited in their reporter activity. Reduction of
AXIN2 expression confirmed the strong repressing effect of IWP12 in
the SNU182 cell line, while no reduction was observed in the other
cell lines (Figure 5B). Overall, this analysis shows that IWP12
treatment barely affects β-catenin signaling activity in most HCC cell
lines, with the exception of SNU182.
In a true tumor setting, in addition to autocrine signaling, HCC
cells are also exposed to Wnt ligands coming from the tumor
microenvironment. Therefore, to determine the effects on β-catenin
signaling of increased levels of extracellular Wnt ligands, we exposed
them to L-Wnt3A conditioned medium. As shown in Figure 5C,
β-catenin reporter activity was strongly enhanced in the Huh7 cell
line and clearly activated in SNU182, both of which were confirmed
by qRT-PCR for AXIN2 (Figure 5D). Importantly, none of the
β-catenin or AXIN1 mutant HCC lines showed enhanced β-catenin
signaling following the addition of L-Wnt3A conditioned medium.
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lines appear largely insensitive to the level of Wnt ligand exposure for
sustaining intracellular β-catenin signaling, which could either mean
that the expressed mutant β-catenin or AXIN1 protein determines
overall signaling levels in a dominant fashion or, alternatively, that
these cells have defects in their machinery to transduce Wnt signals. To
test the latter option, we determined pDVL2 levels following treatment
with IWP12 or L-Wnt3A conditioned medium (Figure 5E).
Phosphorylation levels were not changed in Huh6, and only a modest
reduction was observed in HepG2 following IWP12 treatment. In
contrast, the SNU398 cell line showed a robust response in pDVL2
levels, decreasing from 21% to 7% by IWP12 treatment and
upregulating to 59% following Wnt3A treatment. Thus, both options
may hold true depending on the specific cell line under investigation.
High variability in pDVL2 response was also observed in the remaining
AXIN1-mutant and nonmutant HCC cell lines. The PLC/PRF/5 cell
line showed a low baseline pDVL2 level, which was altered neither by
IWP12 nor Wnt3A. The Huh7 and Hep3B cell lines also showed low
baseline levels, which can however clearly be increased by the addition
of Wnt3A. On the other hand, most DVL2 was phosphorylated at
baseline in SNU182, which can be inhibited by IWP12, but can hardly
be further stimulated by the addition of Wnt3A. Lastly, SNU449 andHepaRG showed intermediate pDVL2 levels at baseline that can be
both reduced and activated by the respective treatments. Thus, all HCC
cell lines show a large variation in both their baseline levels of pDVL2 as
well as responsiveness to Wnt ligand exposure irrespective of their
mutation status.
Response of CRC Cell Lines to Alterations in Wnt Ligand
Levels
Among the eight CRC cell lines treated with IWP12, only
HCT116 showed a significant reduction in β-catenin reporter activity
as well as AXIN2 expression (Figure 6, A and B). AXIN2 expression
was slightly reduced in HT29 and SW480, whereas CACO2 showed
a reduced reporter activity only. Interestingly, HCT116 was also the
only cell line in which both reporter activity and AXIN2 expression
could be significantly stimulated by the addition of extracellular
Wnt3A (Figure 6C and D). Analysis of pDVL2 levels in a selection of
5 CRC lines showed that overall baseline levels were low with the
exception of HCT116 in which 60% of DVL2 is phosphorylated
(Figure 6E). IWP12 treatment shows the expected decrease in
pDVL2 in HCT116, whereas none of the other cell lines showed
clear alterations in pDVL2 levels following treatment with either
IWP12 or Wnt3A.
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Figure 5. Growth reduction due to decreased Wnt secretion appears independent from β-catenin signaling. (A) β-catenin reporter activity
was not clearly reduced by IWP12 in most HCC cell lines, except for SNU182 (mean ± SD, n= 3). (B) QRT-PCR for AXIN2 showed that its
expression following IWP12 treatment was only reduced significantly in the SNU182 cell line (mean ± SD, n= 3, two times). (C) L-Wnt3A
conditioned medium significantly promoted β-catenin signaling activity in Huh7 and SNU182 cell lines. A significant albeit modest
reduction of reporter activity was observed in HepG2 (mean ± SD, n=3). (D) Increased β-catenin signaling in SNU182 and Huh7 following
L-Wnt3A treatment was confirmed by AXIN2 qRT-PCR (mean ± SD, n = 3, two times). All qRT-PCR and reporter values are depicted
relative to the numbers obtained for the controls, which are arbitrarily set to 1. *P b .05; **P b .01. (E) Phosphorylation level of DVL2
protein following treatment with IWP12 or L-Wnt3A conditioned medium (“Con” is DMSO only, “L-Con” is L-Control conditioned
medium). Values below the images represent percentage of total DVL2 that is in the phosphorylated form (upper band).
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Blocking Wnt secretion using IWP12 orWLS knockdown reduces
growth of HCC cell lines, apparently largely independent of β-catenin
signaling. These treatments however also predict the accumulation of
Wnt ligands in the ER, which may lead to activation of an ER stressresponse thereby reducing proliferation or inducing apoptosis.
Therefore, ER stress was evaluated after IWP12 treatment in HCC
cell lines using the expression of the ER-stress induced genes CHOP
and GRP94 as a readout. As shown in Figure 7, A and B, expression
of CHOP was clearly increased in SNU398 (4.5-fold), whereas
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Figure 6. Responsiveness of CRC cell lines to alterations in Wnt ligand levels. (A) β-catenin reporter activity was significantly reduced by
IWP12 in CACO2 and HCT116 cell lines (mean ± SD, n= 3). (B) QRT-PCR for AXIN2 showed that IWP12 treatment reduced its expression
in HCT116. Modest but significant reductions were observed in HT29 and SW480 cell lines (mean ± SD, n = 3, two times). (C) L-Wnt3A
conditioned medium only increased β-catenin reporter activity significantly in HCT116 (mean ± SD, n= 3).(D) AXIN2 qRT-PCR confirmed
upregulation of β-catenin signaling due to L-Wnta3A in HCT116. Significant but modest increases in AXIN2 expression are seen in SW48
and DLD1 (mean ± SD, n=3). Reporter values are depicted relative to the numbers obtained for the controls, which are arbitrarily set to 1.
*P b .05; **P b .01. (E) Top image shows comparison of baseline pDVL2 levels within a selection of five CRC cell lines. Bottom images
show pDVL2 levels following treatment with IWP12 or L-Wnt3A conditioned medium (“Con” is DMSO only, “L-Con” is L-Control
conditioned medium). Values below the images represent percentage of total DVL2 that is in the phosphorylated form (upper band).
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none of the other HCC cell lines displayed strong signs of induction.
Overall, these results suggest that blocking Wnt secretion is not
associated with the induction of a strong ER stress response.
Wnt Secretion Inhibition Does Not Induce Autophagy
Because knockdown of β-catenin or suppression of β-catenin
signaling induced autophagy and even autophagic cell death in head
and neck squamous cell carcinoma cells [35] and breast cancer
stem-like cells [36], we further hypothesized that blocking Wnt
secretion could exert similar effects on HCC cell lines. During
autophagy, the microtubule-associated protein 1A/1B-light chain 3
(LC3) is converted through lipidation into a lower migrating isoform
(LC3-II) detectable by Western blot, which is used as an indicator of
autophagosome formation. As indicated in Figure 7C, IWP12
treatment does not change the LC3 pattern in any of the HCC cell
lines, showing that it does not induce autophagy.
Discussion
In this article, we have investigated the importance of β-catenin
signaling and Wnt secretion for sustaining hepatocellular carcinoma
growth. Using a panel of nine HCC cell lines, we show that β-catenin
signaling is required to support optimal growth in all of them, in line
with other reports using a limited number of cell lines [37,38]. This is
to be expected for cell lines carrying oncogenic β-catenin mutations in
which the activating mutation will have provided a selective growthA BIWP12 5uM
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Figure 7. IWP12 treatment does not lead to the induction of a stron
treatment, the expression of the ER stress induced response genes C
3). Except for a clear induction of CHOP in SNU398 and GRP94 in SNU
in other cell lines. Values depicted are relative to those obtained for
**P b .01. (C) Wnt secretion inhibition does not enhance autophagy
expression of LC3-II was tested by Western blot.advantage during tumor formation, but it also holds true for the
nonmutant ones that show only low levels of baseline signaling, such
as Huh7 and HepaRG, as well as the AXIN1 mutant lines. The latter
observation is of relevance as it has been debated whether AXIN1
mutations lead to a significant enhancement of β-catenin signaling
within liver cancers. This subset of tumors apparently lacks a robust
nuclear β-catenin accumulation and shows no clear upregulation of
target genes such as AXIN2 or GLUL [39,40]. Also in our hands, the
AXIN1 mutant lines are among the lowest expressors of AXIN2.
Nevertheless, in these lines, AXIN2 was readily detectable by
qRT-PCR (Ct values below 28), in addition to β-catenin reporter
activities approaching those of the β-catenin mutant ones. Given that
also these lines are suppressed in their growth following β-catenin
knockdown, it shows that the majority of HCCs independent of their
mutational profile rely on β-catenin signaling for optimal growth.
Besides its role in signaling, β-catenin is also involved in cell-cell
adhesion by directly binding to cadherins [41]. As such, the siRNA
mediated knockdown that we apply here will also likely reduce the
amount of β-catenin sequestered at these adherens junctions.
However, several investigations have shown that complete loss of
β-catenin does not automatically lead to alterations in cell adhesion,
including hepatocytes and hepatocellular cancer cells [42–45]. In all
cases, it was shown that -catenin compensates for its loss, thereby
retaining normal cell adhesion. Importantly, these studies show that it
is mainly the signaling function of β-catenin that is affected following
knockdown.IWP12 5uM
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in HCC cell lines. After incubation with IWP12 for 48 hours, the
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exposure to Wnt ligands contribute to the observed levels of β-catenin
signaling. Using qRT-PCR, we tested the expression of all 19 Wnt
ligands in our cell line panel. The Wnt expression profile that we
observed largely corresponds with the semiquantitative analyses
performed by others [22,46]. WNT3 is the most abundantly
expressed “canonical” Wnt ligand uniformly expressed in all cell
lines, whereas all the others are expressed at low level or only in a
subset of the cell lines. SNU182 clearly stands out as the overall
highest expressor of Wnt ligands, likely explaining the high level of
phosphorylated DVL2 that we observed in this cell line [33]. Among
the nonmutant lines, SNU182 also showed the highest β-catenin
reporter activity and level of AXIN2 expression, comparable with the
β-catenin mutant ones. As such, it is not unexpected that this cell line
strongly relies on Wnt ligand secretion to retain increased β-catenin
signaling. In fact, it is the only HCC cell line that shows a clear
reduction following Wnt secretion blockage on both reporter activity
as well as AXIN2 expression level. On the other hand, the nonmutant
Huh7 cell line expresses the lowest amount of Wnt ligands,
explaining its low baseline signaling levels, but it is highly responsive
to Wnt ligand exposure for inducing strong β-catenin signaling.
Within a true tumor setting, it may represent a subtype of liver
cancers that heavily depends on Wnt ligands expressed by cells within
the tumor microenvironment, whose secretion would also be
inhibited by the porcupine inhibitors employed here, whereas the
SNU182 line is largely autonomous in this respect. Importantly, none
of the β-catenin and AXIN1-mutant HCC cell lines are clearly
affected in β-catenin signaling upon alterations in Wnt ligand
exposure, irrespective of their source, suggesting that the expressed
oncogenic β-catenin or mutant AXIN1 proteins determine overall
signaling levels in a dominant fashion.
In our hands, this also holds true for most of the APC and
β-catenin mutant CRC lines that we investigated. Among eight CRC
lines tested, only HCT116 shows a strongly reduced reporter activity
and AXIN2 levels following IWP12 treatment, although it is also the
only one in which both β-catenin signaling readouts are clearly
increased after Wnt3A exposure. Analysis of pDVL2 levels is largely
in accordance with this lack of response, i.e., most cell lines tested
show only low baseline levels that are barely changed by either
treatment (DLD1, HT29, SW480), suggesting that these lines are
not actively signaling throughWnt ligand receptors. These results also
challenge the universal validity of the conclusions drawn by
Voloshanenko et al. who proposed that colorectal cancers still
strongly depend on Wnt ligand exposure for maintaining optimal
β-catenin signaling levels [26]. Their overall well-performed study
depended on a thorough analysis of the HCT116 cell line and to a
lesser extent on other lines such as DLD1. Importantly, the β-catenin
mutant HCT116 cell line is nowadays known to carry an inactivating
mutation in the transmembrane E3 ubiquitin ligase RNF43, which
strongly sensitizes these cells to exposure by Wnt ligands (see
discussion below) [28,47–49]. As such, their study may have
unknowingly overstated the importance of Wnt ligand signaling for
CRC growth in general, warranting a more extensive analysis in a
larger cohort of CRC samples and cell lines.
In recent years, Wnt secretion inhibitors, such as the porcupine
inhibitor used in our study, have emerged as candidate drugs for
treating Wnt-driven cancers. Cancers that are considered to be
especially responsive to these treatments are the ones carrying somatic
mutations resulting in a persistent presence of Wnt receptors at thecell surface [28,48]. In normal cells, the Wnt/Frizzled receptors are
continuously endocytosed and degraded following ubiquitination by
RNF43 or its close homolog ZNRF3. Both these ubiquitin ligases are
inhibited in their action by one of four secreted R-spondin proteins
[50]. Consequently, mutational inactivation of RNF43/ZNRF3 and
a strongly increased production of R-spondins through the generation
of aberrant fusion transcripts both lead to tumor cells with high levels
of Wnt/Frizzled receptor at their surface and hyperresponsiveness to
Wnt ligands. These genetic aberrations have been identified in 10%
to 20% of CRCs and in various other tumor types [28,51,52] but are,
to the best of our knowledge, not present in HCCs, suggesting that
these tumors are not prime candidates for treatment with Wnt
secretion inhibitors. Nevertheless, our analysis shows that most of the
HCC cell lines are reduced in their growth to varying extents
following both WLS knockdown as well as IWP12 treatment.
The mechanism of the growth suppression remains more elusive at
present. Except for the SNU182 cell line, we do see little evidence of
β-catenin signaling modulation, suggesting that other mechanisms are
at play. One possibility is the induction of ER stress resulting from the
aberrant accumulation of Wnt ligands in the ER. However, except
from increased expression of the ER-induced genes CHOP and
GRP94, in resp. SNU398 and SNU182, we do not see strong
evidence that Wnt secretion blockage leads to high levels of ER stress.
In addition, autophagy did not contribute to the growth suppression
either, as there was no visible change in the pattern of the autophagy
marker LC3 following IWP12 treatment. An alternative explanation
may reside in the reduced secretion of Wnt ligands more commonly
signaling through β-catenin independent pathways. Activation of
these alternative pathways has however mainly been shown to affect
cellular processes involved in migration and cellular polarity and
actually to counteract cell proliferation [8]. This “noncanonical”
pathway has not been extensively studied in liver cancer, but the
available literature does indeed support a growth suppressive effect
[46,53]. Therefore, interfering with the secretion of this subset of
Wnt ligands is expected to support cellular growth, which is in
contrast to the growth suppression that we observed. In line with our
results, Covey et al. have shown that knocking down PORCN in
various tumor cell lines reduced their growth through a
Wnt-independent pathway [54]. Also in their case, no obvious
explanation could be uncovered, but both studies highlight the
importance of considering alternative roles for proteins involved in
Wnt secretion and their role in regulating cell growth.
In conclusion, our study shows that the majority of HCC cell lines
depend on β-catenin signaling for maintaining optimal growth.
Extracellular exposure to Wnt ligands has a minor contribution to
overall β-catenin signaling strength in the β-catenin and
AXIN1-mutant cell lines. Despite this observation, interfering with
Wnt secretion through WLS knockdown or inhibition of porcupine
function results in reduced growth, indicating that these proteins may
have alternative roles currently unappreciated.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.10.004.
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